Drug Information

Drug General Information
Drug ID
D0N0RN
Former ID
DNCL003486
Drug Name
Marizomib
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [550092]
Company
Nereus Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C15H20ClNO4
Canonical SMILES
CC12C(C(=O)NC1(C(=O)O2)C(C3CCCC=C3)O)CCCl
InChI
1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
InChIKey
NGWSFRIPKNWYAO-SHTIJGAHSA-N
PubChem Compound ID
11347535
PubChem Substance ID
16439067, 16939662, 23507068, 26746542, 44388787, 46530726, 57376494, 79829406, 103463910, 104233829, 124490380, 135263373, 137156313, 139895221, 163347632, 179690115, 184811946, 198989908, 224253584, 226516627, 244955810, 252472388
Target and Pathway
Target(s) Proteasome Target Info Inhibitor [531339]
References
Ref 550092Clinical pipeline report, company report or official report of Triphase Accelerator .
Ref 531339Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.